Financial News casts an eye over the industries generating the biggest advisory fees for investment bankers, and which firms are profiting most
1 of 1
Hikma Pharmaceuticals’ bid to acquire German drugmaker Boehringer Ingelheim’s US speciality generics business for $2.65 billion, announced on July 28, is a further shot in the arm for the already burgeoning market for healthcare M&A this year. At $422.8 billion for the year-to-date, it is already close to eclipsing the $429.3 billion total for 2014, according to Dealogic.
